- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01721642
A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device
A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device During and After Transcatheter Aortic Valve Implantation (TAVI) Procedures
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subject age ≥ 18 years of age.
Subjects will be selected in accordance with the investigating centers standard operating procedures for TAVI subject selection and treatment. Subjects selected will meet all of the TAVI inclusion criteria as follows:
- Subject has Senile degenerative aortic stenosis with echocardiography derived criteria: mean gradient > 40 mm Hg or jet velocity > 4.0 m/s or an aortic valve area (AVA) of < 0.8 cm2 (or AVA index < 0.5 cm2/m2.
- Subject is symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class > II.
- Additive EuroScore > 9
- Aortic annulus diameter > 21mm to < 27mm by TEE
- The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
- The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.
- The subject, after formal consults by a cardiologist and two cardiovascular surgeons agreed that medical factors precluding operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeded the probability of meaningful improvement. Specifically the probability of death or serious, irreversible morbidity exceeded 50%.
Exclusion Criteria:
Subjects will be selected in accordance with the investigating centers standard operating procedures for TAVI subject selection and treatment. The following TAVI exclusion criteria shall apply:
- Evidence of an acute myocardial infarction < 1 month before the intended treatment
- Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified
- Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation > 3+)
- Pre-existing prosthetic heart valve in an position, prosthetic ring, or severe (greater than 3+) mitral insufficiency
- Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy.
- Untreated clinically significant coronary artery disease requiring revascularization
- Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices
- Need for emergency surgery for any reason
- Hypertrophic cardiomyopathy with or without obstruction
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months
- A known hypersensitivity of contraindication to asprin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media, which cannot be adequately pre-medicated
- Recent (within 6 months) cerebrovascular accident or transient ischemic attack
- Renal insufficiency and/or end stage renal disease requiring chronic dialysis.
- Life expectancy < 12 months due to non-cardiac co-morbid conditions.
The following ASC device exclusion criteria shall apply:
- Subjects with <10mm Left ventricular wall thickness at apical access site
- LVEF < 30%
- Subject with previous DOR procedure
- Subject access site has less than 2 cm squared "fat" free area under visual observation
- Subject has known Allergy or hypersensitivity to Titanium
- Subject requires MR Imaging post procedure
- Subject is Pregnant
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Apica Cardiovascular ASC Device
Access, stabilisation and closure with the Apica Cardiovascular ASC Device
|
Access, stabilisation and closure of trans-apical approach for TAVI
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Access safety
Prazo: Within 2 hours from initial skin incision
|
Observation of no myocardial tearing on entry of the device
|
Within 2 hours from initial skin incision
|
Closure safety
Prazo: Within 2 hours from initial skin incision
|
Observation of no acute post-procedural bleeding or pericardial effusion.
|
Within 2 hours from initial skin incision
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Investigational device performance: LV function
Prazo: 24 hours, 30 days and 90 days post-procedure
|
% LVEF no worse than baseline as assessed by echocardiography
|
24 hours, 30 days and 90 days post-procedure
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Thomas Walther, Prof, Kerckhoff Klinik
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CIP-DP1
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .